Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-02-13
|
Bekinda™(extended-release formulation of ondansetron) |
acute gastroenteritis |
3 |
Redhill Biopharma (Israel) |
Inflammatory diseases - Gastrointestinal diseases |
2017-02-13
|
bictegravir (GS-9883) |
HIV-1 Infection |
2 |
Gilead Sciences (USA - CA) |
Infectious diseases |
2017-02-13
|
GS-CA1, HIV-1 capsid inhibitors |
HIV-1 infection |
preclinical |
Gilead Sciences (USA - CA) |
Infectious diseases |
2017-02-13
|
HMPL-453 |
solid tumors |
1 |
Hutchison China MediTech Limited (China) |
Cancer - Oncology |
2017-02-13
|
VAL-083 - 1,2:5,6-dianhydrogalactitol |
glioblastoma |
2 |
DelMar Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2017-02-13
|
TD-6450 and faldaprevir |
hepatitis C |
2a |
Trek Therapeutics (USA - MA) Theravance (Ireland) |
Infectious diseases |
2017-02-13
|
dolutegravir (Tivicay®) and rilpivirine (Edurant®) |
HIV-1 infection |
3 |
ViiV Healthcare (UK - USA) Janssen Pharmaceutical , a J&J company (USA - NJ) |
Infectious diseases |
2017-02-10
|
selonsertib (GS-4997) |
NASH (non-alcoholic steatohepatitis) |
3 |
Gilead Sciences (USA - CA) |
Hepatic diseases - Liver diseases |
2017-02-10
|
UCB7665 |
myasthenia gravis |
2 |
UCB (Belgium) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2017-02-10
|
Ocaliva® (obeticholic acid - OCA) |
NASH (non-alcoholic steatohepatitis) |
3 |
Intercept Pharmaceuticals (USA - NY) |
Liver diseases - Hepatic diseases |
2017-02-09
|
cladribine |
relapsing remitting multiple sclerosis (RRMS) |
3 |
Merck KGaA (Germany) |
Neurodegenerative diseases |
2017-02-08
|
Opdivo® (nivolumab)+Yervoy® (ipilimumab) |
non-small cell lung cancer |
1b-2 |
BMS (USA - NY) |
Cancer - Oncology |
2017-02-08
|
A001 - adenovirus associated viral vector serotype 5 containing the human RPE65 gene |
Leber’s Congenital Amaurosis with RPE65 mutations |
1-2 |
MeiraGTx (USA - NY) |
Rare diseases - Genetic diseases - Ophtalmological diseases |
2017-02-08
|
Xarelto® (rivaroxaban) |
prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) |
3 |
Bayer Healthcare (Germany) |
Cardiovascular diseases |
2017-02-07
|
Actimab-A - Lintuzumab-Ac225 |
refractory multiple myeloma |
1 |
Actinium Pharmaceuticals (USA - NJ) Baylor Research Institute, |
Cancer - Oncology |
2017-02-07
|
risankizumab |
psoriasis |
3 |
Abbvie (USA - IL) |
Autoimmune diseases - Dermatological diseases |
2017-02-06
|
glepaglutide (ZP1848) |
short bowel syndrome |
2 |
Zealand Pharma (Denmark) |
Rare diseases - Gastrointestinal diseases |
2017-02-06
|
ADAIR (Abuse-Deterrent, Amphetamine Immediate-Release) |
Attention Deficit Hyperactivity Disorder (ADHD) |
1 |
Alcobra (Israel) |
CNS diseases - Mental diseases - Neurological diseases |
2017-02-06
|
NeuVax™ (nelipepimut-S) in combination with trastuzumab (Herceptin®) |
node positive and triple negative, node negative breast cancer patients with immunohistochemistry HER2 1+/2+ expressing tumors who are disease-free after standard of care therapy |
2b |
Galena Biopharma (USA - OR) |
Cancer - Oncology |
2017-02-06
|
AVXS-101 |
spinal muscular atrophy (SMA) Type 1 |
1 |
Avexis (USA - TX) |
Rare diseases - Genetic diseases - Neuromuscular diseases |